Opinion|Videos|August 15, 2024
TRANSCEND CLL 004 Data Review and its Impact on Future Treatment Practices
Key opinion leaders analyze the implications of the FDA's accelerated approval for lisocabtagene maraleucel (liso-cel) in chronic lymphocytic leukemia, based on promising results from the TRANSCEND CLL 004 trial.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly comment on the recent FDA accelerated approval granted to lisocabtagene maraleucel (liso-cel) based on the findings from TRANSCEND CLL 004.
- How may this impact future treatment practices? In which patients may you consider this treatment approach?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
Data for fixed-duration regimens in CLL suggest benefits over chemoimmunotherapy but still require improvements for high-risk patients.
Orelabrutinib produced efficacy improvements vs chemoimmunotherapy in previously untreated chronic lymphocytic leukemia.
Matthew S. Davids, MD, MMSc, discusses data from BRUIN CLL-322 that may shake up the CLL treatment paradigm.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC
3
Sacituzumab Govitecan Yields Responses in Platinum-Resistant Ovarian Cancer
4
How Are Treatment Intensification and Sequencing Reshaping Care in Prostate Cancer and RCC
5